Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions

Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions

Objective: The purpose of this study was to analyze the difference in duration of anticoagulation and dose of warfarin required to reach a therapeutic international normalized ratio [(INR) of 2 to 3] in patients with hypercoagulable conditions as compared to controls. To our knowledge, this study is...

Full description

Bibliographic Details
Main Authors:	Pushpinderdeep Kahlon, Shahzaib Nabi, Adeel Arshad, Absia Jabbar, Ali Haythem
Format:	Article
Language:	English
Published:	Galenos Publishing House 2016-11-01
Series:	Turkish Journal of Hematology
Subjects:	international normalized ratio warfarin hypercoagulable conditions venous thromboembolism
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-49225

Similar Items

Trends of Ordering Hypercoagulability Work-Up at an Academic Medical Center
by: Alidoost M, et al.
Published: (2021-05-01)

Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Perioperative Hypercoagulable State
by: Songping CUI, et al.
Published: (2019-12-01)

Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis
by: Jeffrey Wagner, et al.
Published: (2019-01-01)

Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps
by: Brian A. Boone, et al.
Published: (2018-06-01)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
by: Zhuang Liu, et al.
Published: (2023-04-01)

Dabigatran versus Warfarin for the Treatment of Pediatric Thromboembolism: A Pilot Randomized Trial
by: Aziz Eghbali, et al.
Published: (2020-09-01)

Hypercoagulable workup in a community hospital setting: to test or not to test; that is the question
by: Ashish Gupta, et al.
Published: (2019-09-01)

Venous thromboembolism in burn patients – low incidence or underdiagnosis?
by: Mirela Tiglis, et al.
Published: (2022-12-01)

Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis
by: Zoe H. Tu, PharmD, et al.
Published: (2024-05-01)

The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial
by: Bundarika Suwanawiboon, et al.
Published: (2022-12-01)

Prevalence of Nosocomial Venous Thromboembolic Complications in New Tuberculosis Patients and Relapses: Data from the Moscow City Registry (A Multicenter Study)
by: D. V. Plotkin, et al.
Published: (2024-03-01)

Frequency and risk factors of venous thromboembolic complications in patients with active pulmonary tuberculosis and HIV/TB co-infection (tuberculosis and thrombosis)
by: Plotkin Dmitriy, et al.
Published: (2024-01-01)

ADVANTAGES AND DISADVANTAGES OF WARFARIN AND PRADAXA THERAPY FOR VENOUS THROMBOEMBOLISM
by: B. S. Sukovatykh, et al.
Published: (2018-01-01)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
by: Neil A. Zakai, et al.
Published: (2021-08-01)

Rate-related hypercoagulable state in mitral stenosis with atrial fibrillation: Can strict rate control prevent thrombus formation?
by: Prashanth Panduranga, FRCP (Edin.)
Published: (2015-12-01)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
by: Pamela L. Lutsey, et al.
Published: (2019-10-01)

Clinical Utilization and Cost of Thrombophilia Testing in Patients with Venous Thromboembolism
by: Manila Gaddh, et al.
Published: (2020-07-01)

Temporal Changes in Long‐Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era
by: Kazuhisa Kaneda, et al.
Published: (2024-08-01)

Hyperglycemia and Venous Thromboembolism
by: Neha Panchagnula, et al.
Published: (2024-09-01)

In Potential Stroke Patients on Warfarin, the International Normalized Ratio Predicts Ischemia
by: Cathy Cao, et al.
Published: (2017-08-01)

Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study
by: Benyapha Sombat, et al.
Published: (2023-06-01)

Bupropion-warfarin combination: A serious complication
by: Amar D Bavle, et al.
Published: (2013-01-01)

OPTIMIZATION OF PROPHYLAXIS OF HYPERCOAGULATION COMPLICATIONS IN ONCOLOGICAL SURGERY
by: A. M. Karsanov, et al.
Published: (2018-01-01)

Characteristics of Laboratory Biomarkers Associated with Hypercoagulability in Lung Cancer Patients During Perioperative Period and Its Diagnostic Value for Deep Venous Thrombosis
by: FANG Qiang, et al.
Published: (2019-12-01)

A rare case of miliary tuberculosis presenting with saddle pulmonary embolism
by: M. Kasim Malik, et al.
Published: (2023-01-01)

Direct Oral Anticoagulants in Patients With Active Cancer
by: Jolanda Sabatino, MD, PhD, et al.
Published: (2020-09-01)

Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study
by: Laura Gillespie, et al.
Published: (2021-04-01)

THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY
by: T. V. Kozlova, et al.
Published: (2016-01-01)

FAMILIAL MEDITERRANEAN FEVER AND HYPERCOAGULABILITY
by: Oshrat E. Tayer-Shifman, et al.
Published: (2011-05-01)

FAMILIAL MEDITERRANEAN FEVER AND HYPERCOAGULABILITY
by: Oshrat E. Tayer-Shifman, et al.
Published: (2011-01-01)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
by: Sirote Luengsupabul, et al.
Published: (2020-06-01)

Warfarin and its role in the prevention of thromboembolism in atrial fibrillation (lecture)
by: Y. V. Shubik
Published: (2015-12-01)

Comparison of the Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients with or Susceptible to Thromboembolic Events
by: Foroud Shahbazi, et al.
Published: (2023-09-01)

Cerebral Venous Sinus Thrombosis induced By Hypercoagulation in Patient With Systemic Lupus Erythematosus: A Case Report and Literature Review
by: Amalia L
Published: (2023-01-01)

COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
by: M. Domenica Cappellini, et al.
Published: (2009-12-01)

COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
by: Alessia Marcon, et al.
Published: (2009-06-01)

Evaluation of hemostasis in hyperthyroid cats
by: Audrey E. Keebaugh, et al.
Published: (2021-11-01)

Hypercoagulation syndrome at liver cirrhosis
by: I. A. Kurkina, et al.
Published: (2014-12-01)

International Normalized Ratio Response Subsequent to Modest Increase in Vitamin K Intake in Patients Treated with Warfarin
by: Mona Foroughi, et al.
Published: (2016-05-01)

The recent clinical trials on use of the novel direct oral anticoagulants in patients with venous thromboembolism: a review
by: Gualtiero Palareti
Published: (2014-10-01)